Shlomo Yanai - Amneal Pharmaceuticals Independent Director
| 2DT Stock | EUR 7.30 0.25 3.31% |
Insider
Shlomo Yanai is Independent Director of Amneal Pharmaceuticals since 2019.
| Age | 66 |
| Tenure | 5 years |
| Phone | 908 947 3120 |
| Web | https://www.amneal.com |
Shlomo Yanai Latest Insider Activity
Tracking and analyzing the buying and selling activities of Shlomo Yanai against Amneal Pharmaceuticals stock is an integral part of due diligence when investing in Amneal Pharmaceuticals. Shlomo Yanai insider activity provides valuable insight into whether Amneal Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Amneal Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amneal Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Shlomo Yanai over a year ago Acquisition by Shlomo Yanai of 1759 shares of Philip Morris subject to Rule 16b-3 | ||
Shlomo Yanai over a year ago Exercise or conversion by Shlomo Yanai of 80128 shares of Amneal Pharmaceuticals subject to Rule 16b-3 |
Amneal Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0257 % which means that it generated a profit of $0.0257 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8759) %, meaning that it generated substantial loss on money invested by shareholders. Amneal Pharmaceuticals' management efficiency ratios could be used to measure how well Amneal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Stephen Koch | Reliance Steel Aluminum | 56 | |
| Hilde Aasheim | Norsk Hydro ASA | 65 | |
| Arvid Moss | Norsk Hydro ASA | 65 | |
| Therese Holm | Norsk Hydro ASA | N/A | |
| Pal Kildemo | Norsk Hydro ASA | 39 | |
| Dag Sigurd | SIVERS SEMICONDUCTORS AB | 73 | |
| Sean Mollins | Reliance Steel Aluminum | 44 | |
| Ash Rajendra | Superior Plus Corp | N/A | |
| Eivind Kallevik | Norsk Hydro ASA | 56 | |
| CCLP CMA | Superior Plus Corp | 62 | |
| AnneLene Midseim | Norsk Hydro ASA | 55 | |
| Tomas Duffy | SIVERS SEMICONDUCTORS AB | 62 | |
| Allison Miller | NMI Holdings | N/A | |
| Robert Smith | NMI Holdings | 53 | |
| Ingrid Engstrom | SIVERS SEMICONDUCTORS AB | 59 | |
| Arthur Ajemyan | Reliance Steel Aluminum | 47 | |
| Karla Lewis | Reliance Steel Aluminum | 57 | |
| Ravi Mallela | NMI Holdings | 53 | |
| MBA MBA | Superior Plus Corp | 70 | |
| Rick Carron | Superior Plus Corp | N/A | |
| James Devens | Superior Plus Corp | N/A | |
Management Performance
| Return On Equity | -0.88 | |||
| Return On Asset | 0.0257 |
Amneal Pharmaceuticals Leadership Team
Elected by the shareholders, the Amneal Pharmaceuticals' board of directors comprises two types of representatives: Amneal Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amneal. The board's role is to monitor Amneal Pharmaceuticals' management team and ensure that shareholders' interests are well served. Amneal Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amneal Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sanjay Jain, President - India | ||
| Anastasios Konidaris, Chief Financial Officer, Senior Vice President | ||
| Shlomo Yanai, Independent Director | ||
| John Kiely, Independent Director | ||
| Gautam Patel, Director | ||
| Nikunj Patel, Head Ltd | ||
| Chintu Patel, Co-Chief Executive Officer, Co-Founder, Director | ||
| Stephen Manzano, Senior Vice President General Counsel & Corporate Secretary | ||
| Sanjiv Patel, VP Operations | ||
| Emily Alva, Independent Director | ||
| Paul Meister, Independent Chairman of the Board | ||
| Nikita Shah, Chief Human Resource Officer, Senior Vice President | ||
| Jason Esq, Chief VP | ||
| Andrew Boyer, Executive Vice President - Commercial Operations | ||
| Anthony DiMeo, Director Relations | ||
| Joseph Greer, Senior Vice President - Global Quality Management | ||
| Apurva Saraf, Senior Vice President - Corporate Development | ||
| RPh RPh, CoCEO CoFounder | ||
| J Buchi, Independent Director | ||
| Chirag Patel, President, Co-Chief Executive Officer, Director | ||
| Ted Nark, Independent Director | ||
| Joseph Todisco, Senior Vice President - Specialty Commercial | ||
| Jeffrey George, Independent Director |
Amneal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amneal Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.88 | |||
| Return On Asset | 0.0257 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 2.95 B | |||
| Shares Outstanding | 151.48 M | |||
| Shares Owned By Insiders | 10.80 % | |||
| Shares Owned By Institutions | 67.79 % | |||
| Price To Earning | 8.70 X | |||
| Price To Book | 1.17 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Amneal Stock
Amneal Pharmaceuticals financial ratios help investors to determine whether Amneal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amneal with respect to the benefits of owning Amneal Pharmaceuticals security.